Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 11/20 | 1.00 |
| ▸ | NEU1 | Q99519 | 11/20 | 1.00 |
| ▸ | NEU3 | Q9UQ49 | 7/20 | 1.00 |
| ▸ | NEU4 | Q8WWR8 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neu5Ac2En SCHEMBL22263416 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL10054709 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL19454809 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL14080015 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL2631455 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL24387783 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL13839147 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| Neu5Ac2En SCHEMBL21125943 | 1.00 | NEU2 (1.00) | NEU2NEU1NEU3NEU4 | |
| SCHEMBL21126049 | 0.89 | NEU1 (0.80) | NEU2NEU1NEU3NEU4 | |
| SCHEMBL22111620 | 0.89 | NEU1 (0.80) | NEU2NEU1NEU3NEU4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101157-A1 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-04-26 | — | — | US | disclosed |
| US-20120101157-A1 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-04-26 | — | — | US | disclosed |
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | GLYCOMIMETICS, INC (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036386-A1 | Heterobifunctional compounds for selectin inhibition | SELE, SELL, BSG | NEU2 29/4885NEU1 30/4885NEU3 46/4885 |
| US-20120101157-A1 | 4,5-Diamino-3-Halo-2-Hydroxybenzoic Acid Derivatives and Preparations Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH3, HRH2 | NEU2 41/4885NEU1 20/4885NEU3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.